Drug reps will promote Avandia (rosiglitazone) as more effective than metformin for initial therapy of type 2 diabetes

January 2007

Drug reps will promote Avandia (rosiglitazone) as more effective than metformin for initial therapy of type 2 diabetes.

They're citing a new study that suggests patients maintain control longer with rosiglitazone than with metformin or glyburide.

You'll hear that 5-year treatment failures are 32% higher with metformin and 63% higher with glyburide compared to rosiglitazone.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote